Tech Company Financing Transactions
Black Diamond Therapeutics Funding Round
Black Diamond Therapeutics closed a $20 million Series A funding round on 12/12/2018. Backers included Versant Ventures.
Transaction Overview
Company Name
Announced On
12/12/2018
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Versant Ventures (Alex Mayweg)
Proceeds Purpose
Proceeds will allow Black Diamond to advance two to three existing development candidates into the clinic in the next 24 months, and to bolster its platform's ability to rapidly identify precision medicines for mutant cancers intractable to standard care.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
139 Main St. 301
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Email Address
Overview
Black Diamond Therapeutics (Nasdaq: BDTX): A Next-Wave Cancer Precision Medicine Company. Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Epstein
Chief Financial Officer
Thomas Leggett
Chief Operating Officer
Brent Hatzis-Schoch
Chief Scientific Officer
Christopher Roberts
Executive Vice President
Elizabeth Buck
Vice President
Tai-An Lin
Vice President
Matthew Lucas
Vice President
Nigel Waters
Vice President
Karsten Witt
Browse more venture capital transactions:
Prev: 12/12/2018: Tomahawk Robotics venture capital transaction
Next: 12/12/2018: The Riveter venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs